Synthesis of 4(3H)quinazolinimines with selective cytotoxic effect on human acute promyelocytic leukemia cells.

We synthesized a new family of six 4(3H)quinazolinimines based on the reaction between (E)-N-(2-cyanophenyl)benzimidoyl chloride and substituted anilines reaching the formation of their corresponding C2, N3-substituted quinazoliniminium chlorides. This method provides novel, direct and flexible access to diverse substituted 4(3H)quinazolinimines. New compounds obtained following the proposed synthesis were fully characterized and, including the thirteen 4(3H)quinazolinimines synthesized by this method and previously reported by us, were used to study its cytotoxic effect on neoplastic cell lines. The mechanism involved in cell toxicity was also studied. Results showed that these compounds were highly cytotoxic, in particular on Human Promyelocytic Leukemia cells (HL60) and Chronic Myelogenous Leukemia cells (K562) when compared with conventional antineoplastic drugs such as etoposide and cisplatin. The mechanism associated to cytotoxic effect was mainly apoptosis, which not was decreased by antioxidant addition, thereby suggesting that the compounds exert apoptotic death through a mechanism unrelated with oxidative stress.

Synthesis of new asymmetric substituted boron amidines - reactions with CO and transfer hydrogenations of phenylacetylene.

The syntheses of the new asymmetric substituted boron amidines [N'-(2,6-diisopropylphenyl)-N-(pentafluorophenyl)acetimidamide]bis(pentafluorophenyl)borate () and [N'-(2,6-diisopropylphenyl)-N-(4-cyanophenyl)acetimidamide]bis(pentafluorophenyl)borate () were achieved by reaction of one equivalent of HB(C6F5)2 and the respective amidines and . These adducts, bearing electron withdrawing groups, showed thermally induced H2 elimination forming the four-membered cyclic diazaborate derivatives and . These new species were characterized by spectroscopic methods. X-ray diffraction studies have been carried out on , and . To prevent undesired reactions at the nitrile group, one equivalent of B(C6F5)3 was added to yielding the -B(C6F5)3 nitrile adduct . Compound underwent thermally induced dehydrogenation to give the four-membered cyclic diazaborate derivative . CO was inserted into the ring systems of and forming the five-membered diazaborolone derivatives and . Phenylacetylene reacted stoichiometrically with the asymmetric substituted boron amidines , and to give styrene by double H transfer.

Synthesis of 4(3H)quinazolinimines by reaction of (E)-N-(aryl)-acetimidoyl or -benzimidoyl chloride with amines.

An efficient one-step method to access 4(3H)quinazolinimines by reaction of phenylchloroimines with 2-aminobenzonitrile is described. The reaction of (E)-N-(2-cyanophenyl)benzimidoyl chloride with substituted anilines that yields a number of their corresponding C2, N3-substituted quinazoliniminium chlorides or neutral products is also reported. These methods provide direct and flexible access to diverse substituted iminoquinazolines substituted at the C2, N3-positions. All the new compounds were fully characterized and six examples are given with their single-crystal X-ray structure.

Synthesis of [(π-cyano-P-nacnac)Cp] and [(π-cyano-nacnac)Cp]-zirconium complexes, and their remote activation for ethylene polymerization.

In this contribution the synthesis and characterization of two distinct, yet similar, zirconium complexes, [(π-P-nacnac-CN)Cp] and [(π-nacnac-CN)Cp] zirconium dichloride were discussed. In addition to the complexes, Lewis acid adducts [B(C(6)F(5))(3)] of the complexes were isolated and characterized as well. It was found that while structurally similar, the complexes behave distinctly upon adduct formation and in their ethylene polymerizations.

Determination of chromium in urine samples by complexation-supercritical fluid extraction and liquid or gas chromatography.

A method was developed for the determination of chromium as the Cr(acac)(3) complex in urine using SFE and chromatography. Quantitative extractions were achieved when the experiments were carried out under 3000 p.s.i. of pressure, at a temperature of 120 degrees C, with 2.0 ml of methanol, 30 min of static extraction and 5 min of dynamic extraction. The chromium was quantified by GC-FID detection. The calibration graph of Cr(acac)(3) solutions was linear between 0.50 and 43.0 microg ml(-1) of chromium (DL 0.18 microg ml(-1), R=0.9994). The same extracts were quantified by HPLC-340 nm detection. The calibration curve of the Cr(acac)(3) solutions was linear over a range of 0.013 to 60.0 microg ml(-1) (DL 0.02 microg ml(-1), R=0.9999). This method was applied to urine samples from 60 diabetic patients and 21 healthy volunteers. Chromium concentration ranges were 2.5-29.5 microg l(-1) for the diabetics and 5.9-12.3 microg l(-1) for the normal subjects.

Extraction of nitrofurantoin and its toxic metabolite from urine by supercritical fluids. Quantitation by high performance liquid chromatography with UV detection.

A procedure is described for the determination of nitrofurantoin and its toxic metabolite in urine from patients with urinary infection using supercritical fluid extraction (SFE) and liquid chromatography. The standard solution of toxic metabolite (radical anion) was obtained by electrochemical reduction of nitrofurantoin in an aprotic medium and chemical reoxidation with oxygen. In our initial SFE studies to find the adequate extraction parameters, drug solutions were impregnated onto filter paper. Quantitative extractions were achieved when the experiments were carried out under 2500 psi of pressure at a temperature of 80 degrees C (oven and restrictor) after 20 min of static extraction and 5 min of dynamic extraction. The modifier used was acetonitrile (2.0 ml in a 10 ml extraction column). Nitrofurantoin and its toxic metabolite were detected in urine samples. Both compounds were quantified in the extracts by high performance liquid chromatography (HPLC) with detection at 310 nm. The calibration graph of these compounds in acetonitrile was linear between 10.9 and 378.0 muM (R=0.9995) for nitrofurantoin and between 3.0x10(-3) and 21.0 muM (R=0.9992) for the metabolite. The detection limits (LOD) were 12.1 and 0.9 muM, respectively. The drug was administered to two patients during 7 days, and all the urine eliminated between 1 day before and 2 days after administration was analyzed. One patient consumed the drug in the form of microcrystals and the other as macrocrystals.